Future directions for immunotherapeutic intervention against sarcomas Journal Article
| Author: | Maki, R. G. |
| Article Title: | Future directions for immunotherapeutic intervention against sarcomas |
| Abstract: | PURPOSE OF REVIEW: To discuss advances in immunotherapy as pertaining to systemic therapy for sarcomas. RECENT FINDINGS: Developments in immunology will have direct relevance to studies in sarcomas and other cancers in the near future. Vaccines employing peptides are the backbone of many studies today due to issues of cost and ease of production, but intact or transfected whole tumor cells or antigen-pulsed or transfected dendritic cells are now being investigated as the immunogenic principle in sarcomas and other cancers. The importance of dendritic cells in generating immune responses is better appreciated than ever, as is the role of CD4 CD25 regulatory T cells in mediating immune responses. Enhancing costimulatory signals to T cells using anti-CD152 (CTLA4) and other antibodies or expanding anti-tumor cytotoxic T lymphocytes ex vivo are other means to enhance immunity to sarcoma-specific antigens. SUMMARY: As of 2006, few studies are examining the utility of immunotherapy in sarcomas. However, a detailed understanding of the remarkable mechanics of how an immune response is mounted and how T cell activation and/or proliferation can be halted by the tumor will be central to properly design new studies of immunological agents against sarcomas and other cancers. © 2006 Lippincott Williams & Wilkins. |
| Keywords: | osteosarcoma; bone neoplasms; unclassified drug; clinical trial; review; cisplatin; doxorubicin; nonhuman; clinical trials as topic; methotrexate; antineoplastic agent; cell proliferation; lymphocyte proliferation; phenotype; bcg vaccine; dendritic cell; granulocyte macrophage colony stimulating factor; cyclophosphamide; antineoplastic activity; cytotoxicity; ifosfamide; sarcoma; health care cost; cd4+ cd25+ t lymphocyte; lymphocyte activation; immune response; immunotherapy; gamma interferon; cancer vaccine; vaccination; tumor immunity; antigens, cd; muramyl tripeptide; cytotoxic t lymphocyte antigen 4; antigens, cd4; t lymphocyte activation; clinical trials; soft tissue neoplasms; vaccine; suppressor cell; antigens, differentiation; interleukin-2 receptor alpha subunit; delayed hypersensitivity; cross-presentation; cell based gene therapy; ctla4; cd55 antibody; allergy and immunology |
| Journal Title: | Current Opinion in Oncology |
| Volume: | 18 |
| Issue: | 4 |
| ISSN: | 1040-8746 |
| Publisher: | Lippincott Williams & Wilkins |
| Date Published: | 2006-07-01 |
| Start Page: | 363 |
| End Page: | 368 |
| Language: | English |
| DOI: | 10.1097/01.cco.0000228743.72165.86 |
| PUBMED: | 16721132 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 13" - "Export Date: 4 June 2012" - "CODEN: CUOOE" - "Source: Scopus" |
